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Association Between β-Genus
-Genus Human Papillomavirus and Cutaneous Squamous
Cell Carcinoma in Immunocompetent Individuals—A Meta-analysis
Abstract
IMPORTANCE
Existing epidemiological evidence remains controversial regarding the association between β-genus
human papillomavirus (β-HPV) and cutaneous squamous cell carcinoma (cSCC) in immunocompetent
individuals.
OBJECTIVE
We aimed to clarify this association and evaluate type-specific β-HPV involvement.
DATA SOURCES
We performed a systematic literature search of MEDLINE and EMBASE for studies in humans through
June 18, 2014, with no restriction on publication date or language. The following search terms were used:
“human papillomavirus” and “cutaneous squamous cell carcinoma or skin squamous cell carcinoma or
cSCC or nonmelanoma skin neoplasms.”
STUDY SELECTION
Articles were independently assessed by 2 reviewers. We only included case-control or cohort studies, in
immunocompetent individuals, that calculated the odds ratio (OR) for cSCC associated with overall and
type-specific β-HPV.
DATA EXTRACTION AND SYNTHESIS
We first assessed the heterogeneity among study-specific ORs using the Q statistic and I 2 statistic. Then,
we used the random-effects model to obtain the overall OR and its 95% CI for all studies as well as for
each type of HPV. We also tested and corrected for publication bias by 3 funnel plot–based methods. The
quality of each study was assessed with the Newcastle Ottawa Scale.
MAIN OUTCOMES AND MEASURES
Pooled ORs and 95% CIs for overall β-HPV and HPV types 5, 8, 15, 17, 20, 24, 36, and 38 association with
skin biopsy proven cSCC. RESULTS Seventy-nine articles were assessed for eligibility; 14 studies met
inclusion criteria for the meta-analysis and included 3112 adult immunocompetent study participants
with cSCC and 6020 controls. For all detection methods, the overall association between β-HPV and
cSCC was significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the type-specific
analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association with adjusted pooled ORs
(95% CIs) of 1.4 (1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34 (1.19-1.52), 1.38 (1.21-1.59), 1.26
(1.09-1.44), 1.23 (1.01-1.50), and 1.37 (1.13-1.67) respectively. Our subgroup analysis in studies using
only serology for HPV detection showed a significant association between overall β-HPV and HPV
subtypes 5, 8, 17, 20, 24, and 38 with an increased risk of cSCC development.
CONCLUSIONS AND RELEVANCE
This study serves as added evidence supporting β-HPV as a risk factor for cSCC in healthy individuals.
The subgroup analysis highlights this significant association for HPV 5, 8, 17, 20, and 38, which may help
to direct future prevention efforts
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IMPORTANCE Existing epidemiological evidence remains controversial regarding the
association between β-genus human papillomavirus (β-HPV) and cutaneous squamous cell
carcinoma (cSCC) in immunocompetent individuals.
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OBJECTIVE We aimed to clarify this association and evaluate type-specific β-HPV
involvement.
DATA SOURCES We performed a systematic literature search of MEDLINE and EMBASE for
studies in humans through June 18, 2014, with no restriction on publication date or language.
The following search terms were used: “human papillomavirus” and “cutaneous squamous
cell carcinoma or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms.”
STUDY SELECTION Articles were independently assessed by 2 reviewers. We only included

case-control or cohort studies, in immunocompetent individuals, that calculated the odds
ratio (OR) for cSCC associated with overall and type-specific β-HPV.
DATA EXTRACTION AND SYNTHESIS We first assessed the heterogeneity among study-specific
ORs using the Q statistic and I2 statistic. Then, we used the random-effects model to obtain
the overall OR and its 95% CI for all studies as well as for each type of HPV. We also tested and
corrected for publication bias by 3 funnel plot–based methods. The quality of each study was
assessed with the Newcastle Ottawa Scale.
MAIN OUTCOMES AND MEASURES Pooled ORs and 95% CIs for overall β-HPV and HPV types
5, 8, 15, 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC.
RESULTS Seventy-nine articles were assessed for eligibility; 14 studies met inclusion criteria
for the meta-analysis and included 3112 adult immunocompetent study participants with
cSCC and 6020 controls. For all detection methods, the overall association between β-HPV
and cSCC was significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the
type-specific analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association
with adjusted pooled ORs (95% CIs) of 1.4 (1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34
(1.19-1.52), 1.38 (1.21-1.59), 1.26 (1.09-1.44), 1.23 (1.01-1.50), and 1.37 (1.13-1.67) respectively.
Our subgroup analysis in studies using only serology for HPV detection showed a significant
association between overall β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38 with an
increased risk of cSCC development.
CONCLUSIONS AND RELEVANCE This study serves as added evidence supporting β-HPV as a
risk factor for cSCC in healthy individuals. The subgroup analysis highlights this significant
association for HPV 5, 8, 17, 20, and 38, which may help to direct future prevention efforts.
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C

utaneous squamous cell carcinoma (cSCC) is one of the
most common cancers in men and women worldwide,
with more than 700 000 newly diagnosed cases yearly
in the United States alone, compared with less than 15 000
newly diagnosed cases yearly of cervical cancer.1,2 The annual incidence of cSCC has increased at an alarming rate in the
last 3 decades, with around 8000 attributable deaths yearly,
twice the death rate from invasive cervical cancer. Furthermore, the estimated annual cost of treating cSCC cases in the
United States is about $3.8 billion. This highlights the important public health burden that cSCC places on our health care
system.3,4 Therefore, a deeper understanding of cSCC’s risk factors should help us to develop more effective preventive measures, in turn decreasing the number of newly diagnosed cases
and the financial burden.
The known risk factors implicated in the development of
cSCC are UV radiation exposure, immunosuppression, and fair
skin.5 In the context of the recent increase in the rates of newly
diagnosed cSCC, a viral etiology has been hypothesized, with
human papillomavirus (HPV) being the major incriminated
virus.6-8 Human papillomaviruses are a large and diverse group
of more than 170 subtypes with 5 major HPV genera: α papillomavirus, β papillomavirus, γ papillomavirus, μ papillomavirus and ν papillomavirus.9,10 β-Genus HPV (β-HPV) is the most
detected genus in cancerous, precancerous, and normal keratinocytes. The analysis of human papillomatous skin lesions and
their relationship to virus infections and carcinogenesis had a
slow start because they were considered a cosmetic problem
with no significant medical implications. This view gradually
changed after 1922, when Lewandowsky and Lutz described a
hereditary condition characterized by an extensive verrucosis,
called epidermodysplasia verruciformis (EV). The first description of β-HPV infection and cutaneous carcinoma was mainly
the work of Stefania Jablonska, who pointed out the potential
role of HPV 5 and 8 in these warts as causal factors for the subsequent development of cSCC.11,12 This later led the International Agency of Research on Cancer (IARC) to consider β-HPV
types 5 and 8, found in 90% of cSCC lesions of EV cases, as possibly carcinogenic. Also, the increased occurrence of cSCC in
solid organ transplant recipients has been associated with significantly higher rates of β-HPV.13,14 More recently, the association of β-HPV and cSCC in immunocompetent individuals was
evaluated in multiple epidemiological case-control studies6,8
with controversial results.
The molecular pathways explaining β-HPV’s implication
in the carcinogenesis of cSCC are not yet fully clarified and
could be explained by a number of mechanisms of action, including the following 3 pathways: (1) Increased susceptibility
to UV-induced oncogenesis in transgenic mice expressing HPV
type 38 E6 and E7 oncoproteins15-17; (2) HPV type 8 E6 oncoprotein’s capacities to inhibit the PDZ (Psd95-DlgA-ZO1) domain protein syntenin-2, a critical element in the control of viral oncogenic potential (the downstream pathway for
syntenin-2 remains to be fully understood)18,19; and (3) β-HPV
types 5, 8, 20, and 38 through E2, 6, and 7 oncoprotein increase the quantity of stem cell–like cells available during early
carcinogenesis, thus enabling the persistence and accumulation of DNA damage necessary to generate malignant stem cells.
jamadermatology.com
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Figure 1. Flow Diagram of Systematic Literature Search
for the Meta-analysis
916 Records identified and screened
through database search
837 Records excluded based
on title and abstract
79 Full-text articles assessed for
eligibility and their reference
lists examined for relevant articles
8 Records identified through
reference lists
73 Records excluded
67 Did not meet inclusion criteria
1 Duplicate study population
5 Did not report ß-HPV or
ß-HPV subtype adjusted OR
14 Records (studies) included in
the meta-analysis

β-HPV indicates β human papillomavirus; OR, odds ratio.

These pathways are only a few of the many plausible molecular mechanisms for type-specific β-HPV involvement in the initiation and progression of the onocogenic process in cSCC.
However, type-specific β-HPV epidemiological evidence remains controversial. Thus, the primary endpoint of this metaanalysis is to evaluate the existing epidemiological data on
type-specific β-HPV association with cSCC in immunocompetent individuals.

Methods
Databases and Search Strategy
We systematically searched for studies in humans through June
18, 2014, with no language restrictions or specified start date.
We searched the MEDLINE and EMBASE databases using the following search terms: “human papillomavirus or HPV or β-HPV”
and “cutaneous squamous cell carcinoma or skin squamous cell
carcinoma or cSCC or nonmelanoma skin neoplasms.” The initial inquiry was conducted by one of us (J.C.) and independently verified by the university medical reference librarian. In
addition, to ensure comprehensiveness, we examined the reference lists from retrieved articles for supplementary relevant
studies. The results were uploaded to Mendeley, a citation
database program for review and selection.

Eligibility Criteria
Eligibility was restricted to studies, with human immunocompetent participants only, that examined the association between HPV and cSCC development as primary episode. Studies were excluded if their outcome of interest was the
development of melanoma, cutaneous basal cell carcinoma,
anogenital cSCC, or recurrent cSCC. As for study design, casecontrols and cohorts of at least 40 patients were eligible for inclusion, while we excluded abstracts, letters to the editor, case
(Reprinted) JAMA Dermatology December 2016 Volume 152, Number 12
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Table. Characteristics of Studies Meeting Search Inclusion Criteria
Source
Masini et al,20 2003
Feltkamp et al,11 2003
Karagas et al,21 2006
Casabonne et al,22 2007
Waterboer et al,23 2008
Bouwes Bavinck et al,24 2010

Design and
Population
Case-control
Cases: 46
Controls: 84
Case-control
Cases: 161
Controls: 386
Case-control
Cases: 252
Control: 461
Case-control
Cases: 39
Controls: 80
Case-control
Cases: 43
Controls: 77
Case-control
Cases: 689
Controls: 845

Multicenter/
Latitude
No/41.54° N

β-HPV Detection Methods/
Subtypes
ELISA serology
HPV types 8,15, 36

No/52.16° N

ELISA serology
HPV types 5, 8, 15, 20, 24, 38

No/44° N

Multiplex serology
HPV types 5, 8, 15, 20, 24, 36,
38 and overall β-HPV
Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38
Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38, and overall β-HPV
Multiplex serology
HPV types: 5, 8, 15, 17, 20, 24,
36, 38
EBH DNA by PCR
HPV types: 5, 8, 20, 24, 36
Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38, and overall β-HPV

No/51.7° N

No/41.54° N

Yes/NA

Karagas et al,25 2010

Case-control
Cases: 663
Controls: 805

No/40° N

Plasmeijer et al,26 2011

Cohort: 1311
cSCC newly
diagnosed: 150
Cohort: 850 000
Cases: 633
Controls: 633
Case-control
Cases: 64
Controls: 57

No/26° S

Case-control
Cases: 173
Controls: 300
Case-control
Case: 155
Control: 371
Case-control
Cases: 156
Controls: 320

No/28° N

Andersson et al,27 2012
Struijk et al,28 2006

Iannacone et al,29 2012
Struijk et al,30 2003
Termorshuizen et al,31 2004

Iannacone et al,32 2014

Case-control
Cases: 168
Controls: 290

Yes/60° N

No/26° S

No/52.16° N

No/52.16° N

No/28° N

Multiplex serology
HPV types 5, 8, 15, 20, 24, 36,
38, and overall β-HPV
Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38 and overall β-HPV
ELISA Serology: HPV types 8,
15, 24 and overall β-HPV
EBH DNA by PCR: HPV types 5,
8, 15, 20, 24, 36, 38 and
overall β-HPV
Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38 and overall β-HPV
EBH DNA by PCR
HPV types 5, 8, 15, 20, 24, 38
ELISA serology
HPV types 5, 8, 15, 20
EBH DNA by PCR: HPV types 5,
8, 15, 20
EBH DNA by PCR
HPV types 5, 8, 15, 20, 24, 36,
38 and overall β-HPV

Newcastle-Ottawa Score/
Adjustment
7
Adjusted for age, sex, eye color, and history
of lifetime exposure to sunlight
6
Adjusted for age and sex
9
Adjusted for age, sex, and skin sensitivity
8
Adjusted for age, sex, and region of
residence
8
Adjusted for age, sex, eye color, and history
of lifetime sun exposure
9
Adjusted for age and sex

9
Adjusted for age, sex, level of education,
cigarette smoking, skin sensitivity, and
number of lifetime painful sunburns
8
Adjusted for age and sex; used Cox
proportional hazards
9
Adjusted age, sex and country
7
Adjusted for age and sex

8
Adjusted for age and sex
7
Adjusted for age and sex
6
Adjusted for age and sex

8
Adjusted for age, sex, education, hair color
sunlight exposure, tanning ability, and
ever-smoking status

Abbreviations: β-HPV indicates β human papillomavirus; EBH, eyebrow hair.

reports, review articles, case-controls (<20 cases and <20 controls), and cohort studies (<40 patients). Studies including less
than 40 patients were excluded, because they lacked statistically significant power. Furthermore, studies not reporting the
associated risk for at least 2 of the HPV subtypes 5, 8, 15, 17,
20, 24, 36, and 38 were excluded from the analysis. To be included in our analysis, studies had to report type-specific
β-HPV odds ratio (OR) or relative risk (RR) with 95% CIs. Restrictions were not placed on the method of detection of HPV.

Selection Process
Two of us (J.C.) and (A.S.) independently reviewed the titles
and abstracts of the previously searched databases. Based on
the prespecified selection criteria, both authors independently identified studies. Disagreements were resolved by discussion with a prior agreement that any unsettled conflict
would be determined by a third author (A.G.R.).
1356

Data collection forms were used by both authors to extract the required data from eligible studies. Then both authors assessed extracted studies for duplication by comparing authors’ names, dates of publication, and population sizes.
Both authors were unblinded to the studies’ authors’ names,
population sizes, journals of publication, and locations.

Data Extraction
Primary outcome measures were ORs with the corresponding 95% CIs for the association of β-HPV and primary episodes of cSCC. We identified the ORs reflecting the greatest degree of adjustment for possible confounding factors. The
adjusted ORs with 95% CIs for overall β-HPV, HPV types 5, 8,
15, 17, 20, 24, 36, and 38 were extracted, when applicable. Other
data of interest included study general information: first author name, year of publication, location, and estimated latitude where the study population was enrolled. Information on
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study design, population size and characteristics, the method
of HPV detection, and the number of β-HPV subtypes analyzed was also collected. In certain circumstances when required data were not reported, authors corresponded with
study authors via email.

Assessment of Bias Risk
Two of us (A.S. and J.C.) independently used the NewcastleOttawa Scale (NOS) for assessing the individual quality of each
study. We used ORs to approximate RR given the rare disease
assumption. We first assessed the heterogeneity among studyspecific ORs using the Q statistic and I2 statistic. We also tested
and corrected for publication bias by 3 funnel plot–based methods: the Egger test, the Begg test, and the trim & fill method.

Statistical Analysis
The meta-analysis was performed on qualifying studies that
had reported adjusted ORs of the association between global
and type-specific β-HPV with cSCC regardless of the detection method. As for the subgroup analyses, they were restricted to studies using seroprevalence detected by multiplex serology or enzyme-linked immunosorbent assay (ELISA).
The adjusted ORs with 95% CIs were identified based on the
meta-analysis results. Random-effects method was used to
pool the ORs and 95% CIs. All study analyses were performed
using the R (R Development Core Team, 2008) and metafor
package (Wolfgang Viechtbauer, 2010).

Results

Original Investigation Research

of each study region.33 We determined that 11 studies were conducted in the northern hemisphere between estimated latitudes 40° N to 60° N, while only 2 studies were conducted in
the southern hemisphere at an estimated latitude of 26° S. All
included studies assessed cSCC as primary outcome in both
controls and cases by skin biopsy pathological evaluation. All
14 studies adjusted for age and sex when calculating the β-HPV
and cSCC associated ORs. Only 8 studies also adjusted for 1 or
more of the following: skin sensitivity, region of residence, eye
color, number of lifetime painful sun burns, smoking history,
or lifetime exposure to sunlight. The most used detection technique for different types of HPV was serology by multiplex polymerase chain reaction (PCR) (8 studies); the ELISA assay was
used in 4 studies and eyebrow hair DNA in 5 studies. ELISA serology is a less sensitive and specific method, compared with
multiplex serology, and was used only in studies published between 2003 and 2006 when multiplex serology was not readily available. Serology is a highly cost-effective HPV detection method, because it allows for large-scale studies as well
as tracking a population over time for analyses in HPV infections. Previous studies32,34 have shown acceptable comparability in sensitivity between β-HPV collected by eyebrow hair,
serology, and surgical biopsy. The selection of the β-HPV subtypes included in both our meta-analysis and subgroup analysis was based on the number of studies evaluating each subtype: β-HPV 8 and 15 (13 studies); β-HPV 5, 20, 24, and 38 (12
studies); β-HPV 36 (10 studies); and β-HPV 17 (7 studies). HPV
type 17 is one subtype of interest that was not evaluated in most
studies. Additional information and extracted data from the
included studies are presented in eTable 1 in the Supplement.

Study Screening

Study Quality

The literature search of the MEDLINE and EMBASE databases
yielded 916 articles. After review of the titles and abstracts, 837
articles were excluded for lack of adherence to our inclusion criteria. We reviewed the full text of the selected 79 articles and assessed their reference lists for relevant publications, retrieving
8 additional publications. Based on this review, we excluded 67
publications for nonadherence with the inclusion criteria. Furthermore, 1 publication was excluded for data overlap with another study, and we included the one with the highest adjustment
for OR in the meta-analysis. We also excluded 5 publications for
not providing the associated risk of β-HPV subtypes, based on
our correspondence with the authors. The flow diagram of the
systematic literature review is illustrated in Figure 1.

Quality assessment was performed using the Newcastle
Ottawa scale, which is specifically used for nonrandomized
studies and has been endorsed by the Cochrane collaboration. We adequately used the version for case-control studies
or cohort studies as applicable, addressing subject selection,
study comparability, and the assessment of outcome or exposure. NOS scores from 6 to 9 (9 being the highest possible score),
with a mean of 7.8, median and mode of 8. All studies earned
a star for comparability with regard to age and sex adjustment. Eight studies received an additional star for comparability, because they also adjusted for skin sensitivity, region
of residence, or lifetime exposure to sunlight. A summary of
the included study evaluation as assessed using the NOS is
shown eTable 2 in the Supplement.

Study Characteristics
The studies included in our meta-analysis comprised 12 casecontrol studies and 2 cohort studies (Table).11,20-32 Publication years ranged from 2003 to 2014, with data collected from
as late as 1992. All studies included adult immunocompetent
participants, males and females of all ages, a total of 3112 cases
and 6020 controls. Our subgroup analysis comprised 12 studies that exclusively used serology as the HPV detection method
and included 2789 cases and 5359 controls. Because UV light
exposure is a major risk factor for cSCC and has been implicated as a cofactor with β-HPV in the initiation of carcinogenesis in multiple molecular models, we evaluated the latitude
jamadermatology.com

Publication Bias
Publication bias was not detected for the pooled studies, or
the subgroup analysis studies using the Egger test35 and the
Begg test.36 We also conducted sensitivity analyses on both
the pooled studies and the subgroup data sets to evaluate
the potential impact of publication bias on the conclusions.
We specifically applied the trim and fill method to evaluate
the subgroup analysis data set and imputed 5 studies.37 The
corrected ORs remained similar to the uncorrected ones,
suggesting that the impact of the publication bias for this
subgroup is small.
(Reprinted) JAMA Dermatology December 2016 Volume 152, Number 12
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Figure 2. Forest Plot for the Studies on the Association of HPV 5, 8, 15, 17, and 20 With cSCC
Study, year
HPV-5 (I2: 25%)
Bouwes Bavinck et al,24 2010
Bouwes Bavinck et al,24 2010
Iannacone et al,32 2014
Struijk et al,30 2003
Iannacone et al,29 2012
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
HPV-8 (I2: 53%)
Bouwes Bavinck et al,24 2010
Bouwes Bavinck et al,24 2010
Iannacone et al,32 2014
Struijk et al,30 2003
Iannacone et al,29 2012
Struijk et al,28 2006
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
Masini et al,20 2003
HPV-15 (I2: 50%)
Bouwes Bavinck et al,24 2010
Bouwes Bavinck et al,24 2010
Iannacone et al,32 2014
Struijk et al,30 2003
Iannacone et al,29 2012
Struijk et al,28 2006
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
Masini et al,20 2003
HPV-17 (I2: 0%)
Bouwes Bavinck et al,24 2010
Bouwes Bavinck et al,24 2010
Iannacone et al,32 2014
Iannacone et al,29 2012
Andersson et al,27 2012
Karagas et al,21 2006
Waterboer et al,23 2008
Casabonne et al,22 2007
HPV-20 (I2: 14%)
Bouwes Bavinck et al,24 2010
Bouwes Bavinck et al,24 2010
Iannacone et al,32 2014
Struijk et al,30 2003
Iannacone et al,29 2012
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003

Cases/Controls, No.

Positive, %

645/807
675/829
168/290
81/212
173/300
43/45
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333

16.90/9.05
29.04/24.25
24.40/17.24
44.44/22.17
20.23/12.67
18.60/24.44
10.74/NA
9.33/NA
6.49/5.09
27.91/28.57
12.82/20.00
11.11/6.72
1.25/0.30

645/807
675/829
168/290
72/203
173/300
37/36
47/46
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333
46/84

39.53/28.00
28.44/24.37
17.26/12.07
37.50/18.72
36.42/23.00
5.41/5.56
29.79/4.35
23.70/NA
36.67/NA
19.16/15.28
37.21/16.88
23.08/20.00
16.27/14.75
4.38/0.30
56.52/32.14

645/807
675/829
168/290
71/195
173/300
36/35
43/47
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333
79/84

30.39/22.80
37.04/29.92
5.95/5.86
36.62/15.38
28.90/25.33
2.78/2.86
23.26/6.38
20.70/NA
25.33/NA
22.02/16.65
41.86/24.68
10.26/18.75
10.32/8.89
4.38/2.10
62.03/47.62

645/807
675/829
168/290
173/300
633/NA
663/805
43/77
39/80

31.78/23.54
17.33/15.92
22.02/14.48
35.26/25.67
23.06/NA
20.21/16.40
46.51/27.27
20.51/15.00

645/807
675/829
168/290
96/254
173/300
46/40
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333

20.00/12.76
26.37/19.9
8.33/6.21
53.12/35.04
29.48/21.00
23.91/15.00
20.70/NA
11.33/NA
19.76/15.16
30.23/29.87
23.08/21.25
9.92/6.07
5.00/2.10

RR (95% CI)

Favors Association Favors No Association

1.40 (1.18-1.66)
2.05 (1.49-2.82)
1.28 (1.02-1.61)
1.19 (0.66-2.15)
1.90 (1.03-3.50)
1.68 (0.95-2.97)
0.59 (0.16-2.19)
1.20 (0.82-1.75)
1.00 (0.54-1.84)
1.45 (0.90-2.34)
0.60 (0.21-1.75)
0.60 (0.14-2.55)
1.80 (1.02-3.17)
2.60 (0.21-32.83)
1.39 (1.16-1.66)
1.68 (1.35-2.10)
1.23 (0.98-1.55)
1.09 (0.55-2.17)
1.80 (0.94-3.46)
1.80 (1.14-2.84)
0.44 (0.05-3.98)
9.30 (1.90-45.56)
1.00 (0.78-1.27)
1.10 (0.80-1.51)
1.45 (1.07-1.96)
1.20 (0.51-2.84)
1.10 (0.40-3.01)
1.20 (0.80-1.80)
14.70 (1.60-135.02)
3.20 (1.30-7.89)
1.25 (1.04-1.50)
1.48 (1.17-1.87)
1.38 (1.11-1.71)
0.94 (0.35-2.54)
2.50 (1.30-4.80)
0.93 (0.58-1.49)
0.64 (0.04-10.61)
3.80 (0.91-15.83)
1.10 (0.85-1.42)
1.00 (0.68-1.46)
1.49 (1.11-2.00)
2.80 (1.10-7.11)
0.50 (0.12-2.06)
1.30 (0.77-2.20)
1.20 (0.40-3.60)
0.40 (0.19-0.85)
1.34 (1.19-1.52)
1.51 (1.20-1.91)
1.11 (0.84-1.46)
1.23 (0.67-2.26)
1.59 (1.02-2.48)
1.20 (0.90-1.60)
1.37 (1.02-1.84)
2.60 (1.02-6.60)
1.40 (0.48-4.06)
1.38 (1.21-1.59)
1.71 (1.29-2.27)
1.44 (1.13-1.84)
1.33 (0.53-3.33)
1.70 (1.00-2.89)
1.41 (0.88-2.26)
0.86 (0.20-3.70)
1.20 (0.90-1.60)
0.60 (0.33-1.10)
1.45 (1.08-1.95)
0.90 (0.37-2.20)
1.10 (0.41-2.96)
1.70 (0.93-3.10)
2.20 (0.74-6.58)
0.1

1.0

10

OR (95% CI)

The squares and horizontal lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The diamond represents the pooled OR and 95% CI of the
overall population. The vertical dashed line indicates the overall pooled OR of 1.33. cSCC, cutaneous squamous cell carcinoma; HPV, human papillomavirus;
NA, not available; OR, odds ratio; RR, relative risk.
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Figure 3. Forest Plot for Studies on the Association Between HPV 24, 36, and 38, and β-HPV and cSCC
Study, year

Cases/Controls No.

HPV-24 (I2: 14%)
Bouwes Bavinck et al,24 2010
645/807
Bouwes Bavinck et al,24 2010
675/829
32
Iannacone et al, 2014
168/290
30
Struijk et al, 2003
84/221
29
Iannacone et al, 2012
173/300
28
Struijk et al, 2006
44/41
Struijk et al,28 2006
41/48
27
Andersson et al, 2012
633/NA
26
Plasmeijer et al, 2011
150/NA
Karagas et al,25 2010
663/805
23
Waterboer et al, 2008
43/77
22
Casabonne et al, 2007
39/80
21
Karagas et al, 2006
252/461
11
Feltkamp et al, 2003
160/333
HPV-36 (I2: 42%)
Bouwes Bavinck et al,24 2010
645/807
Bouwes Bavinck et al,24 2010
675/829
Iannacone et al,32 2014
168/290
Iannacone et al,29 2012
173/300
Andersson et al,27 2012
633/NA
Plasmeijer et al,26 2011
150/NA
Karagas et al,25 2010
633/805
Waterboer et al,23 2008
43/77
Casabonne et al,22 2007
39/80
Karagas et al,21 2006
252/461
Masini et al,20 2003
46/84
HPV-38 (I2: 60%)
Bouwes Bavinck et al,24 2010
645/807
Bouwes Bavinck et al,24 2010
675/829
32
Iannacone et al, 2014
168/290
30
Struijk et al, 2003
95/256
29
Iannacone et al, 2012
173/300
28
Struijk et al, 2006
43/49
Andersson et al,27 2012
633/NA
26
Plasmeijer et al, 2011
150/NA
Karagas et al,25 2010
663/805
23
Waterboer et al, 2008
43/77
22
Casabonne et al, 2007
39/80
Karagas et al,21 2006
252/461
Feltkamp et al,11 2003
160/333
HPV-genus β (I2: 45%)
Iannacone et al,32 2014
168/290
Iannacone et al,29 2012
173/300
28
Struijk et al, 2006
63/57
28
Struijk et al, 2006
54/52
27
Andersson et al, 2012
NA/NA
26
Plasmeijer et al, 2011
150/NA
Karagas et al,25 2010
663/805
23
Waterboer et al, 2008
NA/NA
21
Karagas et al, 2006
252/461
Random-effects model using DerSimonian-Laird

Positive, %
22.02/15.24
36.59/32.69
20.83/12.76
46.43/25.34
20.81/12.33
20.45/17.07
19.51/8.33
10.43/NA
14.67/NA
12.67/10.06
37.21/27.27
12.82/20.00
7.14/6.29
13.12/6.61
15.81/9.91
41.78/33.29
6.55/7.59
23.12/17.33
12.95/NA
10.67/NA
8.90/7.20
32.56/24.68
15.38/16.25
4.37/5.64
19.57/8.33
37.67/24.91
27.70/26.06
32.74/17.93
52.63/35.55
24.28/24.67
18.60/30.61
20.54/NA
32.00/NA
18.70/12.05
48.84/27.27
25.64/17.50
13.49/10.85
5.62/2.70
86.90/73.45
73.41/60.33
44.44/40.35
37.04/13.46
NA/NA
70.67/NA
53.09/45.84
NA/NA
32.54/24.73

RR (95% CI)

Favors Association Favors No Association

1.26 (1.09-1.44)
1.57 (1.20-2.05)
1.19 (0.96-1.47)
1.11 (0.58-2.12)
1.40 (0.78-2.52)
1.63 (0.93-2.86)
0.78 (0.19-3.15)
2.60 (0.70-9.68)
0.90 (0.61-1.32)
0.80 (0.50-1.29)
1.53 (1.07-2.18)
1.40 (0.59-3.33)
0.50 (0.12-2.06)
1.20 (0.63-2.30)
1.50 (0.76-2.95)
1.23 (1.01-1.50)
1.71 (1.25-2.34)
1.44 (1.17-1.77)
0.66 (0.26-1.68)
1.13 (0.68-1.89)
1.10 (0.80-1.51)
0.70 (0.42-1.16)
1.49 (0.99-2.25)
1.60 (0.61-4.18)
0.80 (0.22-2.94)
0.80 (0.38-1.70)
2.80 (0.79-9.90)
1.37 (1.13-1.67)
1.82 (1.46-2.27)
1.09 (0.87-1.37)
1.84 (1.04-3.25)
1.50 (0.89-2.52)
0.94 (0.58-1.52)
0.32 (0.09-1.17)
1.30 (1.00-1.69)
0.90 (0.61-1.32)
1.74 (1.27-2.39)
3.00 (1.17-7.70)
1.50 (0.52-4.35)
1.30 (0.80-2.11)
3.00 (1.09-8.29)
1.42 (1.18-1.72)
1.68 (0.88-3.20)
1.93 (1.23-3.02)
0.93 (0.43-2.01)
3.90 (1.41-10.78)
1.30 (1.05-1.62)
1.00 (0.71-1.41)
1.30 (1.04-1.62)
3.30 (1.23-8.89)
1.50 (1.04-2.17)
1.33 (1.26-1.41)
0.1

1.0

10

OR (95% CI)

The squares and horizontal lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The diamond represents the pooled OR and 95% CI of the
overall population. The vertical dashed line indicates the overall pooled OR of 1.33. cSCC, cutaneous squamous cell carcinoma; HPV, human papillomavirus;
NA, not available; OR, odds ratio; RR, relative risk.

Meta-analysis
Type-Specific β-HPV Association With cSCC
Our meta-analysis comprised a total of 14 studies (3112 cases;
6020 controls). In the pooled analysis, overall β-HPV–cSCC association was significant with an adjusted pooled OR of 1.4
(95% CI, 1.2-1.7). For the type-specific analysis, types 5, 8, 15,
17, 20, 24, 36, and 38 showed a significant association with adjusted pooled ORs of 1.4 (95% CI, 1.2-1.7), 1.4 (95% CI, 1.2-1.7),
1.2 (95% CI, 1.0-1.5), 1.3 (95% CI, 1.2-1.5), 1.4 (95% CI, 1.2-1.6),
1.3 (95% CI, 1.1-1,4), 1.2 (95% CI, 1.0-1.5), and 1.4 (95% CI, 1.11.7) respectively (Figure 2 and Figure 3). A random-effects
jamadermatology.com

model was used because heterogeneity was identified among
the 13 studies. Visual inspection of the funnel plot revealed no
publication bias, later confirmed by the Begg adjusted rank correlation test (Figure 4). The funnel plots and their respective
Begg adjusted rank correlation tests are represented in supplement eFigures 1-9 in the Supplement.
Type-Specific β-HPV Association With cSCC: Seroprevalence Only
Our subgroup meta-analysis comprised a total of 12 studies
(2789 cases; 5359 controls). The pooled analysis of the overall β-HPV association with cSCC was significant, with adjusted
(Reprinted) JAMA Dermatology December 2016 Volume 152, Number 12
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Figure 4. Funnel Plot for Studies on the Association
Between β-HPV and cSCC
Funnel Plot for All 111 Datasets
(Egger test: P = .95; Begg test: P = .91; Trim & Fill: No. Missing = 0)
0

Standard Error

0.358

0.716

1.075
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The vertical solid line represents the summary effect estimates, and the dotted
lines are pseudo 95% CIs.

pooled ORs of 1.4 (95% CI, 1.2-1.8), an increased associated risk
of 45% for cSCC development. In respect to the type-specific
pooled analysis, types HPV 5, 8, 17, 20, 24, and 38 were significantly associated with increased risk of cSCC; the adjusted pooled ORs were 1.4 (95% CI, 1.1-1.8), 1.5 (95% CI, 1.21.8), 1.4 (95% CI, 1.2-1.6), 1.3 (95% CI, 1.1-1.6), 1.3 (95% CI, 1.01.6), and 1.4 (95% CI, 1.1-1.8), respec tively. Human
papillomavirus 15 and 36 did not show any significant increased risk for cSCC with respective adjusted pooled OR of
1.1 (95% CI, 0.9-1.5) and 1.11 (95% CI, 0.9-1.4) (Figure 5 and
Figure 6). Heterogeneity was identified among the 12 studies.
The funnel plots and their respective Begg adjusted rank correlation tests are represented in eFigures 10 through 21 in
Supplement 2.

Discussion
This pooled analysis included a large data sample of casecontrol and cohort studies evaluating the association between
type-specific β-HPV and cSCC. The findings suggest that β-HPV
is associated with a 42% increase in the risk of cSCC among immunocompetent individuals. This analysis highlights specifically types 5, 8, 15, 17, 20, 24, 36, and 38, with an associated increased risk of 40%, 39%, 25%, 34%, 38%, 26%, 23%, and 36%,
respectively. Notably, to our knowledge, this study is the largest to evaluate the type-specific β-HPV associated risk of cSCC.
Our subgroup analysis showed similar results with the exception of HPV type 15. In concordance with our pooled analysis,
Aldabagh et al7 performed an extensive meta-analysis evaluating the association of cSCC and β-HPV in both immunocompromised and healthy individuals, restricted to biopsy PCR HPV
detection, and that suggested an increased risk of cSCC associated with HPV. Their analysis was not restricted to immunocompetent individuals and included only studies using biopsy
specimens with PCR-based detection of HPV, with significant
1360

evidence of statistical heterogeneity in the included studies. A
major source of heterogeneity in their analysis was the inclusion of 10 studies that did not strictly account for cutaneous HPV
subtypes. Furthermore, the results did not account for the HPV
type-specific associations, which represents another limitation to their findings.
Moreover, a concordance exists between our epidemiological HPV type-specific findings and the established typespecific molecular explanations of HPV mechanism in cSCC carcinogenesis. Specifically, the E6 proteins of HPV 5 and 8 are
known to inhibit the transforming growth factor β (TGFβ) signaling pathway through degradation of the SMAD3 transcription factor.38,39 A pathway that normally plays an essential role
in the cell cycle, which could negatively affect viral DNA replication and cell transformation. Also, HPV 5 and 8 E6 proteins induce the recruitment of MAML1, which represses the
cutaneous tumor-suppressive Notch signaling pathway, favoring RAS oncogene.40,41 This in turn can upregulate AP1activating Wnt5a signaling in keratinocytes, a classical skin carcinogenesis pathway.15,42 Finally, HPV 5 and 8 E6 expression
increases the carcinogenic potential of UV-B exposure by promoting p300 degradation, thus increasing thymine dimer persistence and UV-induced double-strand breaks.18 However,
HPV 20 has been shown to upregulate the p16INK4a and
Akt–PI3K pathway, interfering with the cell cycle involved in
progression to basal cell carcinoma. It is also known that the
E6 proteins of HPV 20 can prevent UV-treated keratinocytes
from undergoing apoptosis,15,16,38,43 while HPV38 E7 can degrade pRb increasing the lifespan of human keratinocytes by
deregulating the cell cycle.15,44,45 In addition, the activation
of nuclear factor kappa beta is believed to protect β-HPV immortalized human keratinocytes against tumor necrosis factor (TNF) and UV-mediated apoptosis.46 Among all of the identified HPV types in our pooled analysis, only HPV 17 E7 binds
to UBR4, the effect of this interaction contributes to cellular
transformation and anchorage independent growth.41 Interestingly the recent effort by Cohen et al,47 evaluating BRAF induced-cSCC, highlighted HPV 17 as the most frequently isolated genotype. Molecular evidence also supporting the
involvement of β-HPV in cSCC carcinogenesis is the recent discovery of the rs7208422 polymorphism in the EVER2 gene,
which was associated with an increased risk of cSCC in healthy
individuals who did not have EV.48 Previously, it was known
that the homozygous mutations in EVER2 genes cause EV,
which in turn leads to the development of cSCC associated with
β-HPV infections. EVER2 loss facilitates activation of the HPV
5 long control region through a JNK-dependent pathway
facilitating HPV replication and cSCC development.49

Quality of the Evidence
This constitutes the most extensive meta-analysis on the topic.
Although most of the studies included in our meta-analysis
were case-control studies, they were of higher quality, with NOS
scores ranging between 6 and 9. We addressed the interstudy
heterogeneity, a major limitation of previous research on this
topic. First, the statistical tests showed no significant heterogeneity between the included studies in both our metaanalysis and subgroup analysis. Second, to account for the
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Figure 5. Forest Plot for the Subgroup Meta-analysis: Seroprevalence Only
Study, year

Cases/Controls No.

HPV-5 (I2: 33%)
Bouwes Bavinck et al,24 2010
Iannacone et al,29 2012
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
HPV-8 (I2: 63%)
Bouwes Bavinck et al,24 2010
Iannacone et al,29 2012
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
Masini et al,20 2003
HPV-15 (I2: 56%)
Bouwes Bavinck et al,24 2010
Iannacone et al,29 2012
Struijk et al,28 2006
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003
Masini et al,20 2003
HPV-17 (I2: 0%)
Bouwes Bavinck et al,24 2010
Iannacone et al,29 2012
Andersson et al,27 2012
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
HPV-20 (I2: 38%)
Bouwes Bavinck et al,24 2010
Iannacone et al,29 2012
Andersson et al,27 2012
Plasmeijer et al,26 2011
Karagas et al,25 2010
Waterboer et al,23 2008
Casabonne et al,22 2007
Karagas et al,21 2006
Feltkamp et al,11 2003

Positive, %

645/807
173/300
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333

16.90/9.05
20.23/12.67
10.74/NA
9.33/NA
6.49/5.09
27.91/28.57
12.82/20.00
11.11/6.72
1.25/0.30

645/807
173/300
47/46
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333
46/84

39.53/28.00
36.42/23.00
29.79/4.35
23.70/NA
36.67/NA
19.16/15.28
37.21/16.88
23.08/20.00
16.27/14.75
4.38/0.30
56.52/32.14

645/807
173/300
43/47
633/NA
150/NA
663/805
43/77
39/80
252/461
160/333
79/84

30.39/22.80
28.90/25.33
23.26/6.38
20.70/NA
25.33/NA
22.02/16.65
41.86/24.68
10.26/18.75
10.32/8.89
4.38/2.10
62.03/47.62

645/807
173/300
633/NA
633/805
43/77
39/80

31.78/23.54
35.26/25.67
23.06/NA
20.21/16.40
46.51/27.27
20.51/15.00

645/807
173/300
633/NA
150/NA
633/805
43/77
39/80
252/461
160/333

20.00/12.76
29.48/21.00
20.70/NA
11.33/NA
19.76/15.16
30.23/29.87
23.08/21.25
9.92/6.07
5.00/2.10

RR (95% CI)

Favors Association Favors No Association

1.43(1.13-1.82)
2.05 (1.49-2.82)
1.68 (0.95-2.97)
1.20 (0.82-1.75)
1.00 (0.54-1.84)
1.45 (0.90-2.34)
0.60 (0.21-1.75)
0.60 (0.14-2.55)
1.80 (1.02-3.17)
2.60 (0.21-32.83)
1.46 (1.16-1.84)
1.68 (1.35-2.10)
1.80 (1.14-2.84)
9.30 (1.90-45.56)
1.00 (0.78-1.27)
1.10 (0.80-1.51)
1.45 (1.07-1.96)
1.20 (0.51-2.84)
1.10 (0.40-3.01)
1.20 (0.80-1.80)
14.70 (1.60-135.02)
3.20 (1.30-7.89)
1.18 (0.95-1.48)
1.48 (1.17-1.87)
0.93 (0.58-1.49)
3.80 (0.91-15.83)
1.10 (0.85-1.42)
1.00 (0.68-1.46)
1.49 (1.11-2.00)
2.80 (1.10-7.11)
0.50 (0.12-2.06)
1.30 (0.77-2.20)
1.20 (0.40-3.60)
0.40 (0.19-0.85)
1.42 (1.23-1.64)
1.51 (1.20-1.91)
1.59 (1.02-2.48)
1.20 (0.90-1.60)
1.37 (1.02-1.84)
2.60 (1.02-6.60)
1.40 (0.48-4.06)
1.33 (1.08-1.63)
1.71 (1.29-2.27)
1.41 (0.88-2.26)
1.20 (0.90-1.60)
0.60 (0.33-1.10)
1.45 (1.08-1.95)
0.90 (0.37-2.20)
1.10 (0.41-2.96)
1.70 (0.93-3.10)
2.20 (0.74-6.58)
0.1

1.0

10

OR (95% CI)

The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The diamond represents the pooled OR and 95% CI of the overall population.
The vertical dashed line indicates the overall pooled OR of 1.35. HPV indicates human papillomavirus; NA, not available; OR, odds ratio.

different HPV collection and detection methods, we performed a subgroup analysis restricted to studies that employed HPV serology. Third, we individually evaluated the
association of each β-HPV type with cSCC. This type-specific
meta-analysis constitutes another major quality of the
evidence presented in this study.

Study Limitations
One limitation of this study is the effect of UV light that might
represent a confounder.50 We attempted to minimize this effect by addressing it in our study quality assessment. Furtherjamadermatology.com

more, most included studies were case-control studies that recruited from the same latitude level and adjusted for UV
sunlight exposure.
Even though we have found a strong association
between β-HPV and cSCC it is difficult to prove causality as
our analysis is constituted mostly of case-control studies.
However, the findings of 2 large prospective cohort
studies26,27 were in concordance with current evidence suggesting HPV involvement as a causal agent of the initiation
process of cSCC. Moreover, our pooled analysis did not
include every β-HPV type, a limitation that pertains to the
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Figure 6. Forest Plot for the Subgroup Meta-analysis: Seroprevalence Only
Study, year

Cases/Controls, No.

HPV-24 (I2: 35%)
Bouwes Bavinck et al,24 2010
645/807
Iannacone et al,29 2012
173/300
28
Struijk et al, 2006
41/48
27
Andersson et al, 2012
633/NA
26
Plasmeijer et al, 2011
150/NA
Karagas et al,25 2010
663/805
23
Waterboer et al, 2008
43/77
22
Casabonne et al, 2007
39/80
21
Karagas et al, 2006
252/461
11
Feltkamp et al, 2003
160/333
HPV-36 (I2: 43%)
Bouwes Bavinck et al,24 2010
645/807
Iannacone et al,29 2012
173/300
Andersson et al,27 2012
633/NA
Plasmeijer et al,26 2011
150/NA
Karagas et al,25 2010
663/805
Waterboer et al,23 2008
43/77
Casabonne et al,22 2007
39/80
Karagas et al,21 2006
252/461
Masini et al,20 2003
46/84
HPV-38 (I2: 58%)
Bouwes Bavinck et al,24 2010
645/807
Iannacone et al,29 2012
173/300
27
Andersson et al, 2012
633/NA
26
Plasmeijer et al, 2011
150/NA
25
Karagas et al, 2010
663/805
23
Waterboer et al, 2008
43/77
22
Casabonne et al, 2007
39/80
21
Karagas et al, 2006
252/461
11
Feltkamp et al, 2003
160/333
HPV-genus β (I2: 54%)
Iannacone et al,29 2012
173/300
Struijk et al,28 2006
54/52
Andersson et al,27 2012
NA/NA
Plasmeijer et al,26 2011
150/NA
Karagas et al,25 2010
663/805
Waterboer et al,23 2008
NA/NA
Karagas et al,21 2006
252/461
Random-effects model using DerSimonian-Laird

Positive, %
22.02/15.24
20.81/12.33
19.51/8.33
10.43/NA
14.67/NA
12.67/10.06
37.21/27.27
12.82/20.00
7.14/6.29
13.12/6.61
15.81/9.91
23.12/17.33
12.95/NA
10.67/NA
8.90/7.20
32.56/24.68
15.38/16.25
4.37/5.64
19.57/8.33
37.67/24.91
24.28/24.67
20.54/NA
32.00/NA
18.70/12.05
48.84/27.27
25.64/17.50
13.49/10.85
5.62/2.70
73.41/60.33
37.04/13.46
NA/NA
70.67/NA
53.09/45.84
NA/NA
32.54/24.73

RR (95% CI)

Favors Association Favors No Association

1.27 (1.03-1.57)
1.57 (1.20-2.05)
1.63 (0.93-2.86)
2.60 (0.70-9.68)
0.90 (0.61-1.32)
0.80 (0.50-1.29)
1.53 (1.07-2.18)
1.40 (0.59-3.33)
0.50 (0.12-2.06)
1.20 (0.63-2.30)
1.50 (0.76-2.95)
1.21 (0.95-1.54)
1.71 (1.25-2.34)
1.13 (0.68-1.89)
1.10 (0.80-1.51)
0.70 (0.42-1.16)
1.49 (0.99-2.25)
1.60 (0.61-4.18)
0.80 (0.22-2.94)
0.80 (0.38-1.70)
2.80 (0.79-9.90)
1.44 (1.15-1.80)
1.82 (1.49-2.27)
0.94 (0.58-1.52)
1.30 (1.00-1.69)
0.90 (0.61-1.32)
1.74 (1.27-2.39)
3.00 (1.17-7.70)
1.50 (0.52-4.35)
1.30 (0.80-2.11)
3.00 (1.09-8.29)
1.45 (1.17-1.79)
1.93 (1.23-3.02)
3.90 (1.41-10.78)
1.30 (1.05-1.62)
1.00 (0.71-1.41)
1.30 (1.04-1.62)
3.30 (1.23-8.89)
1.50 (1.04-2.17)
1.35 (1.26-1.44)
0.1

1.0

10

OR (95% CI)

The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The diamond represents the pooled OR and 95% CI of the overall population.
The vertical dashed line indicates the overall pooled OR of 1.35. HPV indicates human papillomavirus; NA, not available; OR, odds ratio.

majority of studies assessing the topic. In addition,
the method of HPV collection in our analysis was not PCR
for HPV DNA from skin biopsy, the gold standard for detection. However, previous studies 7,34 demonstrated that
eyebrow hair DNA and multiplex serology are reliable
substitutes.

HPV vaccinations more widely accepted, possibly increasing the compliance rates for all HPV vaccines. A vaccine that
includes these types of β-HPV will also be a major step
toward precision medicine in the prevention of cSCC
in solid organ transplant recipients, stem cell transplant
recipients, and patients with melanoma undergoing BRAF
inhibitor therapy.

Research and Clinical Implications
The concordance between our epidemiological data in
immunocompetent individuals and the molecular plausibility of type-specific involvement of β-HPV type 5, 8, 15, 17,
20, 24, and 38 in cSCC represents the evidence to strongly
suggest a role for the HPV types in viral oncogenesis
described herein. The associated increased risk of cSCC with
these HPV types (30%-45%), the reported morbidity and
mortality associated with cSCC and the increasing cost of
care, constitute a burden on our health care system. This
highlights the need to develop and test the efficacy of incorporating the above mentioned β-HPV subtypes into available HPV vaccines. Moreover, these efforts could render
1362

Conclusions
This article represents, to our knowledge, the most extensive
meta-analysis appraising the epidemiological association of
β-HPV subtypes implicated in the pathogenesis of cSCC. This
meta-analysis provides additional evidence of the involvement of β-HPV in the development of cSCC in immunocompetent individuals. Furthermore, this adds precision to the existing epidemiological findings by highlighting a significant, typespecific HPV association, which in turn is in concordance with
the new arising molecular type-specific evidence.
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NOTABLE NOTES

Aloe Vera in Dermatology—The Plant of Immortality
Valencia Long, MBBS

Aloe vera, or Aloe barbadensis, is perhaps the most ubiquitous plant in
skin care products across the world and was used even in ancient Greece,
Rome, Babylonia, and China. Historical evidence suggests that both the
leaf and pulp of this plant have been used extensively to treat dermatological ailments and were believed to prevent skin senescence,
acne, psoriasis, relieve pruritus, prevent premature graying of the hair,
improve alopecia, and promote wound healing.1 This Notable Note
addresses the myriad of conditions aloe alleviates and provides a brief
historical perspective of this “plant of immortality.”
During the reign of Emperor Nero, around 50 BC, the Greek physician Dioscorides cited aloe as being able to alleviate skin irritation, sunburn, and acne. Subsequently, Pliny the Elder, a physician who lived from
AD 23 to 79, confirmed in his encyclopedia, Natural History, the discoveries of Dioscorides.2 While some studies show that aloe vera may
inhibit growth of Staphylococcus aureus, Shigella flexneri, and other
superficial mycoses-causing fungus, others suggest that it is ineffective
in preventing Propionibacterium acnes–induced acne.1
In ancient Egypt, Cleopatra and Nefertiti incorporated aloe as part
of their daily skin and beauty care. The dead were embalmed with aloe
vera because of its antibacterial and antifungal properties. It was believed that in stopping the physical decomposition process, eternal life
could be attained physically and also spiritually.
Aloe’s antiaging and anti-inflammatory effects were well documented in the Papyrus Eber of 1550 BC. In Sanskrit, the plant is
known as Ghrita-Kumari. Kumar means girl, and it was believed that
this plant provided womanly youthfulness. Modern studies have
shown that aloe gel significantly improves wrinkles and elasticity in
photoaged human skin, increases collagen production in photoprotected skin, and decreases collagen-degrading MMP-1 gene
expression.1
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Alexander the Great was thought to have used aloe juice to heal the
war wounds on his warriors. Aloe was so important to Alexander that
he arranged for transportable carts of planted aloe as supplies during
his numerous battle campaigns. Aristotle even convinced the great conqueror to capture the island of Socotra specifically to gain possession
of the precious aloe groves—allowing Alexander’s army to acquire
sufficient medication to heal the wounds of entire battalions.3
In modern times, mechanistic studies1 have proven that aloe can
enhance the synthesis of glycosaminoglycan components (hyaluronic acid
and dermatan sulfate) in the matrix of a healing wound to increase the
collagen content of the granulation tissue and the degree of crosslinking.
While many studies in modern times have validated the positive
effects of aloe, contradictory observations exist for the treatment of
psoriasis. As Pliny and Dioscorides described in ancient medical texts,2
the true efficacy of aloe vera perhaps also depends on the interplay of
its compounds, its geographic origin, and processing methods.
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